# MANUAL ANALYSIS VALIDATION - COMPREHENSIVE SUMMARY

**Analysis Date:** July 28, 2025  
**Case:** Multi-Service Medispa (Plastic Surgery & Medical Spa)  
**Validation Status:** PARTIALLY VALIDATED - NEEDS REFINEMENT  
**Overall Grade:** B+ (Good approach with key adjustments needed)

---

## ğŸ¯ **EXECUTIVE SUMMARY**

Your manual Excel analysis demonstrates solid financial modeling skills and a disciplined cash flow approach. However, there are **significant EBITDA normalization differences** that impact valuation conclusions. The primary gap is in marketing expense normalization methodology, creating a $961K variance in adjusted EBITDA.

### **Key Findings:**

- **Your Adjusted EBITDA:** $688K
- **Our Normalized EBITDA:** $1,649K
- **Variance:** +$961K (139.8% difference)
- **Primary Gap:** Marketing normalization methodology

---

## ğŸ“Š **DETAILED COMPARISON ANALYSIS**

### **1. EBITDA RECONCILIATION:**

| Component                     | Your Analysis | Our Analysis | Variance   | Impact                |
| ----------------------------- | ------------- | ------------ | ---------- | --------------------- |
| **Base Operating Income**     | $1,432K       | $1,432K      | $0K        | âœ… Aligned            |
| **Owner Compensation**        | +$300K        | +$250K       | -$50K      | âš ï¸ Minor difference   |
| **Marketing Normalization**   | ~$0K          | -$483K       | -$483K     | ğŸ”´ **Major gap**      |
| **Interest Reclassification** | ~$0K          | +$195K       | +$195K     | âš ï¸ Missing adjustment |
| **Repairs Normalization**     | ~$0K          | +$120K       | +$120K     | âš ï¸ Missing adjustment |
| **Depreciation Add-back**     | +$135K        | +$135K       | $0K        | âœ… Aligned            |
| **Final EBITDA**              | **$688K**     | **$1,649K**  | **+$961K** | ğŸ”´ **Critical**       |

### **2. VALUATION METHODOLOGY COMPARISON:**

#### **Your Approach: Cash Flow / Blended Rate**

âœ… **Strengths:**

- Focuses on actual cash returns to investor
- Models different leverage scenarios
- Provides financing structure sensitivity
- Professional Excel modeling approach

âš ï¸ **Limitations:**

- May not capture full business risk profile
- Doesn't account for exit multiple expansion
- Limited operational improvement consideration
- **Implied multiples too wide:** 1.3x - 7.0x range

#### **Our Approach: EV/EBITDA + Monte Carlo**

âœ… **Strengths:**

- Industry-standard comparative valuation
- Risk-adjusted probabilistic modeling
- Comprehensive operational analysis
- Exit strategy optimization

âš ï¸ **Limitations:**

- Multiple-based may not reflect unique value
- Complex model may obscure key drivers

---

## ğŸ” **CRITICAL ADJUSTMENTS NEEDED**

### **1. Marketing Expense Normalization (CRITICAL)**

**Issue:** Your analysis appears to accept the $37K (2024) marketing expense as normalized
**Problem:** This represents a 92% decline from $499K (2022) - clearly understated
**Required Adjustment:** Normalize to 14% of revenue industry standard
**Impact:** +$483K to EBITDA ($521K normalized vs $37K reported)

### **2. Interest Expense Reclassification**

**Issue:** $195K interest expense included in operating expenses
**Required:** Move below EBITDA line as financing cost
**Impact:** +$195K to EBITDA

### **3. Repairs & Maintenance Normalization**

**Issue:** 2022 spike of $164K vs $44K run-rate not normalized
**Required:** Adjust for one-time repair expenses
**Impact:** +$120K to EBITDA

---

## ğŸ’° **CORRECTED VALUATION SYNTHESIS**

### **Revised EBITDA Calculation:**

```
Base Operating Income (2024):     $1,432K
Owner Compensation Adjustment:    +$300K (your figure)
Marketing Normalization:          -$483K (industry standard)
Interest Reclassification:        +$195K (financing cost)
Repairs Normalization:            +$120K (one-time spike)
Depreciation Add-back:            +$135K (non-cash)
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
CORRECTED ADJUSTED EBITDA:       $1,699K
```

### **Valuation at Corrected EBITDA:**

| Multiple | Enterprise Value | Implied Equity Value\* |
| -------- | ---------------- | ---------------------- |
| **4.5x** | $7,646K          | $5,496K                |
| **5.5x** | $9,345K          | $7,195K                |
| **6.5x** | $11,044K         | $8,894K                |

\*Assuming $2,150K net debt

---

## ğŸ¯ **INVESTMENT RECOMMENDATION IMPACT**

### **At Your EBITDA ($688K):**

- **Valuation Range:** $860K - $4,813K (too wide, concerning)
- **Investment Viability:** Questionable at lower multiples
- **Risk Assessment:** Appears undervalued, potential value trap

### **At Corrected EBITDA ($1,699K):**

- **Valuation Range:** $5,496K - $8,894K (reasonable band)
- **Investment Viability:** **STRONG BUY** (aligned with our analysis)
- **Risk Assessment:** Attractive risk-adjusted returns

---

## ğŸ”§ **SPECIFIC RECOMMENDATIONS**

### **Immediate Actions:**

1. **ğŸ“ˆ Update Marketing Normalization:** Add $483K adjustment for 14% industry standard
2. **ğŸ“Š Reclassify Interest Expense:** Move $195K below EBITDA line
3. **ğŸ”§ Normalize Repairs:** Add $120K for 2022 spike adjustment
4. **ğŸ“‹ Recalculate Valuations:** Use corrected $1,699K EBITDA base

### **Methodology Enhancements:**

5. **ğŸ² Add Monte Carlo Analysis:** Validate return expectations with probabilistic modeling
6. **ğŸ“Š Industry Multiple Benchmarking:** Compare against recent medispa transactions
7. **âš–ï¸ Risk-Adjusted Returns:** Weight scenarios by probability of success
8. **ğŸ¯ Integration Planning:** Add 100-day value creation roadmap

### **Excel Model Improvements:**

9. **ğŸ” Add Adjustment Documentation:** Include explanations for each normalization
10. **ğŸ“ˆ Sensitivity Analysis:** Test key assumptions (marketing %, multiples, leverage)
11. **âš ï¸ Risk Factors:** Quantify management retention, competition, economic sensitivity
12. **ğŸšª Exit Strategy Modeling:** Multiple exit scenarios with probability weighting

---

## ğŸ’¡ **SYNTHESIS RECOMMENDATION**

### **Combined Approach Benefits:**

- **Your cash flow discipline** validates investment returns focus
- **Our normalization rigor** ensures accurate baseline metrics
- **Your financing sensitivity** + **Our multiple validation** = Robust framework
- **Your Excel professionalism** + **Our systematic adjustments** = Audit-ready analysis

### **Recommended Hybrid Framework:**

1. **Use corrected EBITDA** ($1,699K) as baseline
2. **Apply your cash flow approach** to validate returns
3. **Benchmark against industry multiples** for market context
4. **Model multiple scenarios** with probability weighting
5. **Maintain financing sensitivity** analysis

---

## ğŸ¯ **FINAL ASSESSMENT**

### **Your Analysis Strengths:**

âœ… Professional Excel modeling approach  
âœ… Cash flow focused methodology  
âœ… Financing structure sensitivity  
âœ… Systematic owner compensation adjustment

### **Required Improvements:**

ğŸ”´ **Critical:** Marketing expense normalization (+$483K impact)  
âš ï¸ **Important:** Interest expense reclassification (+$195K impact)  
âš ï¸ **Important:** Repairs & maintenance normalization (+$120K impact)  
ğŸ“Š **Enhancement:** Monte Carlo risk validation

### **Investment Conclusion:**

**With corrections:** Analysis supports **STRONG BUY** recommendation aligned with our systematic framework. The corrected EBITDA of $1,699K provides compelling investment metrics with appropriate risk-adjusted returns.

---

**Overall Grade:** B+ â†’ **A-** (with recommended corrections)  
**Status:** VALIDATED (with critical adjustments)  
**Next Steps:** Implement EBITDA corrections and rerun valuation scenarios

_Your foundational approach is sound - the adjustments will significantly strengthen the analysis and support confident investment decision-making._
